The national advocacy group for patients with blood-clot disorders says there is a greater risk of getting blood clots from COVID-19 than there is from the vaccine.
Thrombosis Canada issued an updated statement on the risk of blood clots late Thursday, after the European Medicines Agency released its final report on the risk of blood clots after getting the Oxford-AstraZeneca vaccine.
The agency says there is no evidence of increased risk of blood clots from the vaccine, but added there is still not enough evidence to say if the vaccine played a role in a small number of clots in the vein that drains blood from the brain.
Statements from both @GovCanHealth (https://t.co/prHYBU85O7) and @ThrombosisCan (https://t.co/q2DcYM8KMq) confirm that the benefits of the #AstraZeneca #COVID19 vaccine continue to outweigh the risks for use in Canada.
— Nathan Stall (@NathanStall) March 19, 2021
These conclusions fully align with those of the @EMA_News.
Thrombosis Canada, whose board is made up of physicians specializing in blood clots, says the incidence of those clots, known as cerebral sinus vein thrombosis, occurred at a rate between one in 250,000 to one in 500,000 people who received the vaccine.
By comparison, they say blood clots occurred in about one in 20 people hospitalized with COVID-19 and about one in 100 patients who have COVID-19 but were not hospitalized.
At least four European countries that halted AstraZeneca injections pending the review are resuming them, with France, Germany and Italy restarting the vaccinations today and Spain planning to do so next week.
.jpg "Nova Scotia reconsidering joint review of shootings")
